Healthy Skepticism Library item: 15314

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: news

IMS World Pharmaceutical Market Summary March 2009
IMS Health 2009 Mar 21
http://www.imshealth.com/portal/site/imshealth/menuitem.a953aef4d73d1ecd88f611019418c22a/?vgnextoid=bb967900b55a5110VgnVCM10000071812ca2RCRD&vgnextfmt=default

Full text:

Sales Through Retail Pharmacies (Twelve months to December 2008*)

NORTH AMERICA $222.5 billion up 2%
U.S.A. $208.6 billion up 1%
CANADA $16.6 billion up 7%
EUROPE (TOP 5) $114.3 billion up 2%
GERMANY $35.2 billion up 4%
FRANCE $30.6 billion up 0%
UK $15.7 billion down 1%
ITALY $17.2 billion up 1%
SPAIN $15.3 billion up 4%
JAPAN (including hospitals) $68.6 billion up 3%
LATIN AMERICA (TOP 3) $24.2 billion up 10%
BRAZIL $12.4 billion up 12%
MEXICO $8.5 billion up 2%
ARGENTINA $3.2 billion up 23%
AUSTRALIA/NZ $7.8 billion up 10%

The top 5 therapy classes at ATC3 level in the 12 months to December 2008 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to December 2008 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to December 2008 were:
1. Pfizer
2. GlaxoSmithKline
3. AstraZeneca
4. Novartis
5. Sanofi-Aventis ******************************************************
Sales Through Retail Pharmacies (Twelve months to January 2009*)
NORTH AMERICA $222.3 billion up 2%
U.S.A. $205.9 billion up 2%
CANADA $16.3 billion up 6%
EUROPE (TOP 5) $113.0 billion up 1%
GERMANY $34.9 billion up 3%
FRANCE $30.4 billion up 0%
UK $15.3 billion down 1%
ITALY $17.0 billion up 0%
SPAIN $15.2 billion up 4%
JAPAN (including hospitals) $69.9 billion up 2%
LATIN AMERICA (TOP 3) $23.9 billion up 9%
BRAZIL $12.2 billion up 11%
MEXICO $8.3 billion up 1%
ARGENTINA $3.2 billion up 23%
AUSTRALIA/NZ $7.7 billion up 9%

The top 5 therapy classes at ATC3 level in the 12 months to January 2009 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B – Antiulcerants
3. N6A – Antidepressants & mood stabilisers
4. N5A – Antipsychotics
5. N3A – Anti-epileptics
The top 5 products in the 12 months to January 2009 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide/Advair
5. Enbrel
The top 5 corporations in the 12 months to January 2009 were:
1. Pfizer
2. GlaxoSmithKline
3. AstraZeneca
4. Novartis
5. Sanofi-Aventis